UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
University of California, Davis
Thomas Jefferson University
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center